阿托伐他汀对急性冠脉综合征患者血清MMP-9及IL-18的影响

目的：探讨阿托伐他汀对急性冠脉综合征（acute coronary syndrome，ACS）患者血清基质金属蛋白酶-9（matrix metalloproteinase-9，MMP-9）、白介素-18（interleukin-18，IL-18）水平的影响。方法将ACS患者60例随机分为阿托伐他汀组（阿托伐他汀20 mg/d，连续用药14 d）和对照组（除未用阿托伐他汀外，余治疗同阿托伐他汀组）。药物治疗前及治疗14 d后检测血清MMP-9、IL-18水平。结果阿托伐他汀组治疗后MMP-9及IL-18分别是（295±110） mg/L和（399±115） pg/ml]与治疗前分别是（368±97） mg/L和（471±105） pg/ml]比较有下降，差异均有统计学意义（ P＜0．05）；阿托伐他汀组治疗后MMP-9及IL-18水平均明显低于同期对照组分别是（358±95） mg/L和（466±109） pg/ml]，差异有统计学意义（P＜0．05）。结论阿托伐他汀可降低ACS 患者血清MMP-9、IL-18水平，抑制斑块内炎性反应，促进斑块的稳定性。

Effect of atorvastatin on serum levels of matrix metalloproteinase-9 and interleukin-18 in patients with acute coronary syndrome

Objective To investigate the effect of atorvastatin on plasma MMP-9 and IL-18 in patients with acute coronary syn-drome （ ACS ） .Methods Sixty patients with ACS were randomly divided into treatment group （ taking atorvastatin 20 mg/d for 14 days）, control group （no atorvastatin, other treatments were similar to treatment group ）.Before drug therapy and after 14 days, MMP-9 and IL-18 levels in serum were measured .Results Compared with pre-treatment, the levels of MMP-9 and IL-18 in treatment group were decreased （295 ±110）mg/L vs（358 ±95）mg/L;（399 ±115）pg/ml vs（471 ±105）pg/ml ,respectively],these differences were statistically significant （P〈0.05）.Moreover, the levels of MMP-9 and IL-18 in treatment group were significantly lower than those in control group （358 ±95）mg/L,（466 ±109）pg/ml, respectively], these differences were statistically significant （P〈0.05）.Conclu-sions Atorvastatin can decrease serum MMP-9 and IL-18 levels in patients with ACS , which contributes to inhibit plaque inflammation , to advance the stability of plaque .Early intensive atorvastatin treatment may yield more significant benefits to the patients with ACS .